Never Miss Important Company Updates Again
Get AI-powered summaries of SEC filings delivered to your inbox
Follow your favorite stocks and get email alerts when they release important updates. Completely free.
Bioxytran, Inc. is a clinical-stage pharmaceutical company developing therapeutic drugs targeting hypoxia, a condition of oxygen deficiency in tissues. Its lead candidate, BXT-25, is a novel oxygen-carrying small molecule designed to treat stroke-related brain hypoxia. Through its subsidiary Pharmalectin, the company develops galectin antagonist-based therapies for viral diseases, including COVID-19. Bioxytran focuses on innovative co-polymer chemistry, leveraging proprietary technology to address unmet medical needs via licensing partnerships.
This description was generated via AI from an annual report. Updated about 1 year ago.